QuidelOrtho Corporation (QDEL)

Market Cap	2.53B
Revenue (ttm)	2.76B
Net Income (ttm)	-358.70M
Shares Out	67.63M
EPS (ttm)	-5.33
PE Ratio	n/a
Forward PE	14.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,845,349
Open	37.84
Previous Close	36.34
Day's Range	37.30 - 38.99
52-Week Range	23.77 - 49.45
Beta	0.13
Analysts	Buy
Price Target	44.43 (+18.73%)
Earnings Date	May 7, 2025

About QDEL

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease,...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1979
• Employees: 6,600
• Stock Exchange: NASDAQ
• Ticker Symbol: QDEL
• Website: https://www.quidelortho.com

Financial Performance

In 2024, QuidelOrtho's revenue was $2.78 billion, a decrease of -7.17% compared to the previous year's $3.00 billion. Losses were -$2.05 billion, 20216.8% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for QDEL stock is "Buy." The 12-month stock price forecast is $44.43, which is an increase of 18.73% from the latest price.

Price Target

$44.43

(18.73% upside)

Analyst Consensus: Buy